Yongan Pharmaceutical Co., Ltd. (002365.SZ) released its first-quarter performance, with a net loss attributable to shareholders of 4.3672 million yuan.

The Financial News APP reports that Yongan Pharmaceutical (002365.SZ) released its first quarter report for 2025. In the first quarter, the company achieved operating income of 171 million yuan, a year-on-year decrease of 12.96%. The net loss attributable to the shareholders of the listed company was 4.3672 million yuan. The net loss attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 6.6696 million yuan.